NCT00542893: A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine |
|
|
| Completed | 1 | | US | Genasense® (G3139, oblimersen sodium), Genasense followed by DTIC; then DTIC alone, DTIC alone; then Genasense followed by DTIC | Genta Incorporated | Advanced Melanoma | | 09/07 | | |
